Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors
Sign Up to like & getrecommendations! Published in 2024 at "Advances in Therapy"
DOI: 10.1007/s12325-024-03032-3
Abstract: In the Phase 3 XTEND-1 trial, (NCT04161495) efanesoctocog alfa prophylaxis provided superior bleed protection versus pre-study factor VIII (FVIII) replacement therapy in patients with severe haemophilia A. The aim of this study was to indirectly… read more here.
Keywords: efanesoctocog alfa; therapy; fviii replacement; shl ... See more keywords